Immuneering (NASDAQ:IMRX – Get Free Report) and CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Analyst Recommendations
This is a summary of current recommendations for Immuneering and CytomX Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immuneering | 0 | 3 | 4 | 0 | 2.57 |
| CytomX Therapeutics | 0 | 3 | 3 | 0 | 2.50 |
Immuneering currently has a consensus price target of $12.60, indicating a potential upside of 475.34%. CytomX Therapeutics has a consensus price target of $5.77, indicating a potential upside of 401.96%. Given Immuneering’s stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than CytomX Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Immuneering | N/A | -66.03% | -58.78% |
| CytomX Therapeutics | 9.27% | -27.44% | 5.78% |
Institutional and Insider Ownership
67.7% of Immuneering shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 25.0% of Immuneering shares are owned by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Immuneering has a beta of -0.45, suggesting that its stock price is 145% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
Valuation & Earnings
This table compares Immuneering and CytomX Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immuneering | $320,000.00 | 202.94 | -$53.47 million | ($1.87) | -1.17 |
| CytomX Therapeutics | $119.57 million | 0.75 | -$570,000.00 | $0.20 | 5.75 |
CytomX Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
CytomX Therapeutics beats Immuneering on 9 of the 14 factors compared between the two stocks.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
